Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, have been established as first-line treatments for non-small cell lung cancer (NSCLC) patients and have exhibited notable clinical efficacy. However, resistance to TKIs has become one of the major obstacles...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, He, Lu, Binbin, Ren, Shengnan, Wu, Fubin, Wang, Xinxing, Yan, Caiyun, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920314/
https://www.ncbi.nlm.nih.gov/pubmed/31841994
http://dx.doi.org/10.1016/j.omtn.2019.10.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920314/
https://www.ncbi.nlm.nih.gov/pubmed/31841994
http://dx.doi.org/10.1016/j.omtn.2019.10.039

Ejemplares similares